title: Anaemia management in non-dialysis chronic kidney disease: flexibility of target to target stability?
abstract: International clinical practice guidelines have recently recognized for the first time the concrete difficulty of keeping chronic kidney disease (CKD) patients within the narrow haemoglobin (Hb) target recommended of 11-12 g/dl (110-120 g/l) because of the variability of individual patient Hb levels. This emerging clinical problem has been the topic of several editorials that, however, exclusively focused on haemodialysis patients. Recently, 3 retrospective studies have been published on Hb variability in non-dialysis CKD. The studies which overall included more than 6,000 patients showed that Hb variability in non-dialysis CKD is greatly prevalent and is associated with a worse cardiorenal outcome. This minireview summarizes the results and limits of these studies and discusses the potential implications for clinical practice.
authors.affiliation: Nephrology Division, Second University of Naples, Naples, Italy. luca.denicola@unina2.it
authors.forename: Luca
authors.initials: L
authors.lastname: De Nicola
authors.forename: Roberto
authors.initials: R
authors.lastname: Minutolo
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Conte
mesh_terms: D000740:Anemia / Q000097:blood / Q000209:etiology* / Q000235:genetics / Q000628:therapy*; D000818:Animals; D019468:Disease Management; D016503:Drug Delivery Systems / Q000639:trends*; D006397:Hematinics / Q000008:administration & dosage*; D006454:Hemoglobins / Q000037:antagonists & inhibitors / Q000378:metabolism*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000150:complications / Q000235:genetics / Q000628:therapy*; D006435:Renal Dialysis / Q000639:trends
chemical_list: D006397:Hematinics; D006454:Hemoglobins